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Crohn’s Disease and Omega 3: Can it decrease CRP?
A Literature Review
The Crohn’s and Colitis foundation of America estimates that 70,000 Americans are
diagnosed with inflammatory bowel disease (IBD) each year (2021). Crohn's disease is an
inflammatory bowel disease characterized by periods of remission and exacerbation triggered by
an increase in stress (Mackner et al., 2020). Patients can experience debilitating abdominal pain,
diarrhea, fatigue, blood in the stool, and reduced appetite during an exacerbation period, all of
which can lead to life-threatening complications (Mayo Clinic, 2020). In most cases, patients are
diagnosed in their late teens or early adulthood years, and are prescribed anti-inflammatory drugs
(Mayo Clinic, 2020). As there is no true cure for Crohn's disease, medications are never
guaranteed to work and patients are often forced to undergo many therapies before finding the
right regimen for their condition. Currently, in hospitals, there has not been any added
intervention with daily supplements for these patients to assist in treating the inflammation. In
controlled clinical trials, omega-3 fatty acid supplements have statistically shown promise as an
anti-inflammatory agent to aid in Crohn's disease treatment (Natto et al., 2019).
Clinical Problem
At the onset of a flare-up, patients will only take their anti-inflammatory medication. To
date, there have been few to no supplements used together with prescribed Crohn's disease
medications. Omega-3 fatty acid supplements are known to have an anti-inflammatory effect,
and may help reduce inflammation associated with Crohn's disease (Natto et al., 2019). The
following question is posed based on the knowledge that this literature review will evaluate the
amount of inflammation in Crohn's disease patients using the C-reactive protein (CRP) level. Is
the use of a daily omega-3 fatty acid supplement, as evidenced by a lower CRP level, effective in
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reducing or eliminating inflammation in hospitalized Crohn's disease patients? This question is
examined in the subsequent sections.
PICO Question
Following the Population, Intervention, Comparison, Outcome PICO formatting, the
following question is posed. In hospitalized patients diagnosed with Crohn’s disease, does
implementing a daily 3,000mg omega-3 fatty acid supplement upon admission, compared to
treatment with prescribed anti-inflammatories alone, decrease CRP levels? Does the literature
support or refute this intervention?
Search Terms
The databases used for this literature review are EBSCO and PubMed. Search terms used
for this literature review were: Omega-3, Crohn’s Disease, Omega 3 supplement, and Crohn’s
Disease stress. Database research was completed on June 3, 2021. Appendix A displays the
Individual Evidence Summary for each resource. Appendix B displays the Overall Evidence
Summation for each resource that was graded using the Johns Hopkins Nursing Evidence-Based
Practice Model for Evidence Rating Scales.
Literature Review
When a patient is diagnosed with Crohn's disease, most patient education consists of
instructing them to rest and take the prescribed Crohn's medications. The most common
medications prescribed are corticosteroids, oral 5-aminosalicylates, immunosuppressant’s, or
biologics (Mayo Clinic, 2020). As these medications are long-term, the patient must remain
compliant, even when they are feeling well. The discontinuation of certain medications,
including those of the biologic drug class, can cause antibodies to develop in the body against
that drug (University of Michigan, 2021). If this occurs, the medicine may no longer be
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beneficial (University of Michigan, 2021). In addition to the potential for developing antibodies
against the medications, the majority of these medications come with undesirable side effects.
Aminosalicylates have a number of common side effects, including muscle or joint pain, flu-like
symptoms, slight hair loss, sweating, acne, vomiting, and heartburn (Crohn's and Colitis
Foundation of America, 2020).
As prescribed medication is typically the topic of discussion, and alternative approaches
are rarely discussed, many patients are left unaware of other alternatives for reducing flare-ups.
A group of researchers conducted a study for a journal entitled Digestive Diseases and Sciences
to determine the effectiveness of a specific carbohydrate diet, and it proved to be a promising
treatment option (Suskind et al., 2016). An anonymous survey containing 45 questions was sent
to multiple websites for patients to respond with ease (Suskind et al., 2016). Over half of the 417
individuals who responded to the survey reported that they began the diet to avoid medication
(Suskind et al., 2016). After a period of twelve months on the diet regimen, most individuals
reported a significant decrease in symptoms of IBD (Suskind et al., 2016). In order to achieve the
highest quality of life, all treatment options should be thoroughly explained to patients, such as
the use of diet, acupuncture, or omega-3 supplements rather than the use of simply prescribed
Crohn’s medications alone.
Omega-3 fatty acids are an essential fat because the body cannot manufacture it on its
own, so they must be consumed through food or supplements in order to survive (Cleveland
Clinic, 2019). The anti-inflammatory properties of omega-3 fatty acid supplements are attributed
to the fact that it decreases the production of inflammatory molecules, such as cytokines, leading
to improved levels of inflammatory biomarkers (Natto et al., 2019). Studies have not yet been
performed to determine whether omega-3 supplements are effective in helping patients with

CROHN’S DISEASE AND OMEGA 3 SUPPLEMENTS

5

Crohn’s disease; however, studies have shown promise for its effect on other conditions. A
recent study looked at patients with chronic kidney disease to determine whether omega-3
supplementation helped in “general characteristics, nutrition, renal disease markers, and
inflammatory markers C-reactive protein, interleukin (IL)-6, IL-10, and tumor necrosis factor
alpha (Valle Flores et al., 2020). The study found that patients taking omega-3 supplements for
twelve weeks showed a significant decrease in CRP, Il-6, IL-10, and tumor necrosis factor levels
(Valle Flores et al., 2020). However, the placebo-controlled group showed no significant
difference in these measurements (Valle Flores et al., 2020).
Marine omega-3 supplementation was investigated in a meta-analysis to determine its
effects on coronary heart disease, cardiovascular disease, and myocardial infarction risk (Hu et
al., 2019). Marine omega-3 supplements were found to lower the risk of myocardial infarction,
coronary heart disease, and cardiovascular disease, as well as reduce the risk of death from these
conditions (Hu et al., 2019). Aside from omega-3 supplements, certain foods also contain
omega-3 fatty acids. The three main types of omega-3 fatty acids are known as “alpha-linolenic
acid, eicosapentaenoic acid, and docosahexaenoic acid” (NIH, 2021). The most abundant omega3 fatty acid in western diets is alpha-linolenic, as it is found in flaxseed, canola, and soybean oils
(Harvard University, 2019). Eicosapentaenoic acid and docosahexaenoic acid, on the other hand,
can be found in seafood like shrimp or salmon (Harvard University, 2019; NIH, 2021).
In order to measure the effectiveness of these interventions, CRP levels should be
monitored. Serum CRP is, “an acute-phase protein exclusively synthesized by the liver largely
under transcriptional control of IL-6” (Coelho, 2009). CRP begins to secrete within four to six
hours of an inflammatory stimulus being released by the body, and it can remain elevated for
long periods of time in patients with chronic inflammatory diseases (Coelho, 2009). In a CRP
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blood test, C-reactive protein levels are measures with a normal level of less than 10 mg/L and a
level over 10mg/L indicating a high degree of inflammation in the body (Mayo Clinic, 2017). In
inflammatory bowel disease, a CRP test is more closely associated with disease activity than a
complete blood count alone (Chen et al., 2020).
Practice Recommendations
Upon the completion of this literature review, the following three practice
recommendations have been identified. First, patients with Crohn’s disease should have labs
drawn upon admission to the hospital, specifically the CRP level needs to be monitored and
compared to the patient’s primary care CRP labs. While Crohn’s disease cannot be diagnosed
through a CRP blood test, it gives the health care providers a closer look at the degree of disease
activity occurring in the patient. (Crohn’s and Colitis Foundation of America, 2021). Initially,
the patient’s CRP may appear to be at a normal level, however, it can change within four to six
hours of a stimulus making it an important value to closely monitor (Coelho, 2009). This test,
while simple, can indicate how the patient is responding to the treatment allowing the provider to
adjust the treatment plan as necessary.
Second, every patient over the age of 18 that is admitted with Crohn’s disease should be
started on a daily Omega-3 fatty acid supplement of 3,000mg, unless otherwise contraindicated,
along with their prescribed Crohn’s medications. Initially, when providing care to a patient with
Crohn’s disease, physicians will prescribe medications such as corticosteroids or
immunosuppressants, without recommendation for omega-3 supplements (Mayo Clinic, 2020).
According to a study performed by Calder, “studies in healthy human volunteers suggest that an
intake of >2g EPA+DHA/day is required to affect inflammatory processes” (Calder, 2010,
p.365). The high levels of stress associated with hospitalization can trigger a Crohn’s disease
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exacerbation, if the patient not already experiencing one. Adding a daily omega-3 supplement
along with prescribed anti-inflammatory medication in these hospitalized patients with Crohn’s
disease can leading to a decrease in CRP and assist in treating the exacerbation.
Third, nurses can encourage foods high in Omega-3 such as flaxseed oil, canola oil, and
salmon. In addition, patients should receive education regarding an anti-inflammatory diet such
as a specific carbohydrate diet and avoiding a diet high in fiber (Suskind et al., 2016). Treating
Crohn’s disease involves a well-rounded approach by including every aspect of the individual’s
life. This can be done by, decreasing inflammatory foods, adding in foods high in omega-3, and
using omega-3 supplements to, in combination, decrease the patient’s CRP.
Conclusion
Over 70,000 people are diagnosed with Crohn's disease every year, which results in many
painful symptoms and can end in life-threatening complications (Crohn's and Colitis Foundation
of America, 2021; Mayo Clinic, 2020). Therefore, it is imperative that the healthcare system
meets the needs of this population. Since, according to Mackner et al. (2020), stress is a trigger
for inflammation, all patients with a history of IBD should undergo routine CRP testing upon
admission. As a result of this literature review, it can be concluded that anti-inflammatory
medications alone have been the standard treatment for Crohn’s disease. Additionally,
supplements have rarely been used in conjunction with prescribed Crohn’s disease medications
to date. Omega-3 fatty acids have been shown to lower inflammatory biomarkers in patients with
conditions like chronic kidney disease and coronary heart disease (Hu et al., 2019; Natto, 2019;
Valle Flores et al., 2020). Thus, suggesting that diets high in omega-3 supplements and
supplements, along with prescribed Crohn’s medications, may be beneficial in treating patients
with Crohn’s disease.
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Appendix A

Individual Evidence Summary
Databases Used:
EBSCO; PubMed

Article
#

1

Search Terms Used:
Filters Used:
Omega 3; Crohn’s Disease; Omega 3 supplement; Crohn’s Years 2016-2021
Disease stress
Peer-Reviewed Article

Author(s)

Year

Evidence
Type

Sample
Size

Results
Recommendations

Limitations

Natto,
Yaghmoor,
Alshaeri, Van
Dyke

2019

MetaAnalysis of
RCT

N/A

Omega-3 fatty acid
supplements may be associated
with improvements in
inflammatory biomarkers and
lipid profiles.

Mackner et al.

2020

Empirical &
Quantitative

23

Chen, et al.

2020

Retrospective

876

Pediatric patients with Crohn’s
Disease who report high levels
of stress show greater disease
activity in their intestinal
microbiota than patients who
report low stress levels.
In individuals with
Inflammatory Bowel Disease,
CRP and ALB are strongly
correlated with disease
activity.

Researchers used 16
studies to analyze when
696 studies were found
relating to the topic due
to the exclusion criteria
they identified.
Smaller sample size

2

3

The patients
participating in the
study are only from
southeast China, may
not represent larger
population and it is a
retrospective singlecenter study.

Strength
&
Quality
Level I
B

Level II
C

Level III
B

CROHN’S DISEASE AND OMEGA 3 SUPPLEMENTS
Article
#

12

Author(s)

Year

Evidence
Type

Sample
Size

Valle Flores, et
al.

2020

RCT

93

Results Recommendations

Limitations

Strength
&
Quality

In patients with CKD it is
Cost effectiveness of
Level I
4
essential to begin them on an
the trial
A
omega-3 supplement. The
results of the investigation
showed a significant decrease
in concentrations of
inflammatory markers of the
participants.
Suskind, et al.
2016
Survey
417
Dietary therapy, specifically
The majority of internet Level II
5
specific carbohydrate diet
sites the survey was
B
(SCD) are promising in the
sent to are SCDtreatment of Inflammatory
specific so there was
Bowel Disease but further
the likelihood of
studies need to be performed.
response bias.
Hu, et al.
2019 Meta-analysis 127,477
Omega-3 supplementation is
Unable to perform a
Level I
6
of RCT
associated with a lower risk of subgroup analysis and
A
MI, CHD, CVD, and death
the analysis did not
from CVD or CHD
include small trials.
Note: n/a= not applicable, RCT= randomized control trial, CRP= C-reactive protein, ALB= albumin, CKD= chronic kidney disease,
MI= myocardial infarction, CHD= coronary heart disease, CVD=cardiovascular disease, SCD= specific carbohydrate diet
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Appendix B
Overall Evidence Summation
Level of
Evidence

# of Journal
Articles

Summary of Findings

I

3

II

2

III

1

IV

0

Oral Omega-3 fatty acid supplements lead to a decrease
in inflammatory markers in individuals with CKD on
hemodialysis. It is essential that Omega-3 become
regular protocol of diet for CKD. Marine Omega-3
supplementation leads to lower risk of MI, CHD, and
CVD. High doses of marine omega-3 supplementation is
needed to see these results. Omega-3 fatty acids lower
triglycerides from reducing VLDL secretion. Omega-3
may affect insulin metabolism and lipids by reducing
LDL synthesis, working on receptor activity in the liver,
improving glucose tolerance, and increasing AMPK
expression.
Pediatric patients with Crohn’s Disease who report high
levels of stress have greater amounts of disease activity
in their intestinal microbiota. Microbiome difference
between high and low stress patients is independent from
prescribed medication use. A specific carbohydrate diet
has shown decreased clinical symptoms of Crohn’s
disease and positive effects on laboratory values. Diet
should be maintained long term for maximum
effectiveness.
In individuals with Inflammatory Bowel Disease, the
CRP and ALB ratio is strongly correlated with disease
activity. The CRP/ALB ratio should be used over a CBC
to determine disease activity in IBD patients.
N/A

V

0

N/A

Overall
Quality

A

B

B

N/A
N/A

Note: CKD= chronic kidney disease, n/a= not applicable, IBD= inflammatory bowel disease,
CRP= C-reactive protein, ALB= albumin, CBC= complete blood count, MI= myocardial
infarction, CHD= coronary heart disease, CVD= cardiovascular disease, VLDL= very lowdensity lipoprotein, LDL= low density lipoprotein, AMPK= activated protein kinase

